Warning! Senate Report Reveals GlaxoSmithKline Hid Truth about Diabetes Drug Avandia and Heart Attacks


Avandia is a drug used to combat type two diabetes. Avandia is made and marketed by GlaxoSmithKline. Avandia could not be released into the American marketplace without the approval of the Food & Drug Administration, and the FDA indeed approved Avandia.

Now, a U.S. Senate Report has been released that confirms Glaxo Smith Kline knew that diabetes drug Avandia contributed to tens of thousands of heart attacks and didn’t share this bad news with anyone. Not the patients, not the public, not the press solely in order to continue to sell this drug which has made them over $3 billion dollars.

The Senate also points its finger at the FDA. According to the Senate Report, the Food & Drug Administration just brushed off its own scientists when they voiced concerns about Avandia.

Until something is done, diabetics taking Avandia will continue to suffer heart attacks. People are dying and will keep on dying until something is done.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Kenneth J. Allen & Associates | Attorney Advertising

Written by:


Kenneth J. Allen & Associates on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.